HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Lisata Therapeutics (NASDAQ:LSTA) and maintained a $15 price target.
June 14, 2024 | 10:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating on Lisata Therapeutics and maintained a $15 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $15 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100